Navigation Links
MacroGenics and Servier Enter Development and Commercialization Agreement for Novel Anti-Cancer Drug
Date:12/1/2011

ROCKVILLE, Maryland and SURESNES, France, Dec. 1, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, and Servier, France's largest privately-held pharmaceutical company, announced today that they have entered into an option for a license agreement for the development and commercialization of MGA271, MacroGenics' proprietary product candidate.  MGA271 is a first-in-class, Fc-optimized monoclonal antibody that targets B7-H3 and is currently being studied in a Phase 1 clinical trial for the treatment of solid tumors.

MGA271 is a next generation monoclonal antibody which incorporates multiple complementary mechanisms of action including enhanced immuno-stimulatory properties and targeting of tumor vasculature. The B7-H3 target is overexpressed in several malignancies requiring innovative therapeutic approaches.  "Following very promising pre-clinical results, we will work together to define the clinical indications and the best drug combinations and to identify early biomarkers predictive of response," said Stephane Depil, M.D., Ph.D., in charge of Oncology Research & Development at Servier. "Today's announcement underscores Servier's commitment to develop novel targeted therapies that address significant unmet medical needs for cancer patients," added Emmanuel Canet, M.D., Ph.D., President Research & Development at Servier. "MGA271 is a novel immunotherapeutic with a compelling product profile and the potential to treat a broad spectrum of solid tumors. We have been deeply impressed by both the excellence of science being conducted by MacroGenics and their world-class antibody development capabilities. We are looking forward to building a long-term strategic collaboration with MacroGenics."

Under the terms of the agreement, MacroGenics retains full development and commercialization rights to MGA271 in the U.S., Canada, Mexico, Japan, Korea and India, whil
'/>"/>

SOURCE MacroGenics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
2. MacroGenics Announces Presentation of Protege Phase 3 Clinical Data at ADA in San Diego on June 28
3. Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
4. MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
5. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
6. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
7. Intercept Pharmaceuticals and Servier Announce Agreement for Intercepts TGR5 Research Program in Type 2 Diabetes
8. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
9. Zimmer to Establish Asia-Pacific Research and Development Center
10. vRad Selected by Abbeville Area Medical Center for PACS Replacement
11. ETCs Aircrew Training Systems Completes Factory Acceptance Tests for Highly Advanced Suite of Training Equipment for the Republic of Korea Air Force Aeromedical Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... , June 02, 2015 Research and ... of the "The Future of Pharmaceutical Outsourcing" ... they are in a desperate need to develop ... cost, drug companies have been increasingly utilizing external ... productivity while constantly streamlining their internal operation. Their ...
(Date:6/3/2015)... SHANGHAI , June 3, 2015 MEDTEC China South ... an extension of MEDTEC China 2015, MEDTEC China South has ... attributes, standing out as a key event for the medical ... After many years of challenges, this year marks the successful return ... 10 years after the event first debuted there in 2005. ...
(Date:6/3/2015)... , June 3, 2015 Genoa ... Pharmaceuticals, Inc., bringing together two pharmacy organizations with proven ... illness. Both companies have strong reputations for outstanding customer ... Genoa is the ... health community and those affiliated with managing the cost ...
Breaking Medicine Technology:The Future of Pharmaceutical Outsourcing: 2015 Report 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Genoa, a QoL Healthcare Company Acquires Northeast Pharmaceuticals, Inc. 2
... , MORRISTOWN, N.J. , March 11 ... today announced the U.S. Food and Drug Administration (FDA) ... suspension), a new twice-yearly formulation of TRELSTAR®, a proven, ... With an anticipated May launch, TRELSTAR® 22.5 mg is ...
... , THOUSAND OAKS, Calif. , March 11 ... has received a US Patent Office Notice of Allowance ... expressing, secreting, and purifying the NELL-1 sequence of the ... a Chinese hamster ovary (CHO) cell. This patent continues ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 2Bone Biologics Announces Another Major US Patent Issuance for Recombinant Protein Process 3
(Date:6/3/2015)... 03, 2015 blingsting announces their new ... car's glove compartment or can be strapped onto a ... features a pointed tip that will allow the user ... blade that can cut through a seatbelt or carseat ... Glammer include:, ,         Easily break a window ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 EMBARGOED FOR RELEASE ... Birth Weight Associated with Proximity of Mother’s Home to Gas ... close to a high density of natural gas wells drilled ... lower birth weights than women living farther from such wells, ... Public Health analysis of southwestern Pennsylvania birth records. ...
(Date:6/3/2015)... The Canton Group, a leading web ... announced today that Tim Dodge has joined the company ... The Canton Group as it implements an ambitious ... , Tim is a tech industry veteran who has ... technology companies. Before joining The Canton Group, Tim was ...
(Date:6/3/2015)... June 03, 2015 On the heels of ... billion industry by 2020 ( click here to review ... scientists believe Baltimore has the talent to become ... which genetic code and other biological data are collected and ... “Baltimore contains all the elements of a perfect storm ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Alberto Grignolo, ... at DIA’s upcoming Annual Meeting. DIA’s Global Inspire Award ... level of excellence, and commitment to service on a ... Global Connector Award that annually recognizes one DIA member ... advanced the mission of DIA to foster innovation to ...
Breaking Medicine News(10 mins):Health News:blingsting Announces All New Car Safety Tool The Glammer 2Health News:Fracking Proximity Associated with Lower Birth Weight 2Health News:Fracking Proximity Associated with Lower Birth Weight 3Health News:Fracking Proximity Associated with Lower Birth Weight 4Health News:The Canton Group Appoints Tim Dodge as Chief Marketing Officer 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 2Health News:Longtime DIA Champion and PAREXEL Executive Honored with Global Inspire Award at DIA’s Annual Meeting 3
... variety of therapeutic categories can be screened to identify effective ... for publication in the Endocrine Society,s Journal of Clinical ... rapidly be implemented into a clinical trial to test how ... chemical agents capable of modulating a disease is a long ...
... trial found that rilonacept, an inhibitor of the ... that occur when initiating uric acid-lowering therapy. Results ... targeted therapy in prevention of gout flaresshow rilonacept ... infections or treatment-related serious adverse events reported. Full ...
... WEDNESDAY, Jan. 4 (HealthDay News) -- Nearly one in four ... that her risk of getting other sexually transmitted diseases is ... commonly transmitted sexually transmitted infection (STI) in the United States, ... to 19 infected. Some virus types can raise the ...
... women against infection from one of the two types of herpes ... New England Journal of Medicine . The vaccine was ... did not protect women from herpes simplex virus type 2 (HSV-2). ... herpes caused by HSV-1 58 percent fewer -- in women ...
... By Mary Brophy Marcus HealthDay Reporter , ... against the hepatitis C virus, which can cause severe liver ... it,s likely years away, researchers are reporting. , , There ... estimated 170 million people worldwide. , , Like HIV, the ...
... (HealthDay News) -- New research shows that women with ... from depression and so-called "disordered eating," regardless of whether ... that most [study] participants frequently adhered to a gluten-free ... to increased vitality, lower stress, decreased depressive symptoms and ...
Cached Medicine News:Health News:New drug screening identifies chemical agents with potent anti-cancer activity 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 3Health News:Many Teen Girls Mistakenly Think HPV Vaccines Cut Risk for All STDs 2Health News:Many Teen Girls Mistakenly Think HPV Vaccines Cut Risk for All STDs 3Health News:Research shows progress toward a genital herpes vaccine 2Health News:Research shows progress toward a genital herpes vaccine 3Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 2Health News:Novel Hepatitis C Vaccine Shows Some Early Promise 3Health News:Celiac Disease in Women Linked to Depression Risk 2
... The Hoffmann® II Compact™ Upper extremity fixator ... of the distal radius by allowing independent ... One of the main goals has been ... providing total versatility and ease of use. ...
The Small External Fixator has straight or angled frames, independent pin placement, and combines easily with Large and Medium External Fixator frames....
... Fixator is now available in a convenient, ... instrumentation. The surgical technique is printed on ... , ,This fixator allows the surgeon to ... multipaner adjustments in the frame via joints ...
... Fixation System for distal radius fractures allows ... length and rotation. The unique wrist lock ... into extension without losing fracture reduction. Post-op ... the surgeons office. Priced competitively and sold ...
Medicine Products: